Health Update: Early Flu Season and Growing Interest in Shingles Vaccines

Health experts in England are closely watching two different trends this autumn: an early start to the flu season and a surprising rise in demand for the shingles vaccine. While these two issues are different, both have led to more people visiting pharmacies and clinics to seek protection against future health problems.

According to the UK Health Security Agency (UKHSA), flu activity has been higher throughout September than in the same period over the last four winter seasons. While overall levels remain low, the agency noted that emergency department visits for flu-like illnesses are already above what is usually expected for this time of year. Experts suggest that this early rise could mean a more intense flu season ahead, as an earlier start often leads to a longer period of the virus spreading through the community.

Professor Antonia Ho from the University of Glasgow explained that the current increase is being driven largely by young people aged 18 to 24. Two main types of the flu virus, known as H1N1 and H3N2, are currently circulating. While the H1N1 virus has changed slightly from the version used to create this year’s vaccine, experts say it is too early to know if this will reduce the vaccine's effectiveness. Professor Sir Andrew Pollard of the Oxford Vaccine Group stressed that getting vaccinated remains the best way to stay safe, especially for those at higher risk due to their age or underlying health conditions.

While flu vaccinations are a standard part of winter health, a different trend is appearing at high street pharmacies regarding the shingles vaccine. Shingles is a painful rash caused by the same virus that leads to chickenpox. The virus stays in the body for many years and can become active again as people get older or if their immune system becomes weak. Usually, the vaccine is given to older adults to prevent this painful condition. However, data from retailers like Boots and Superdrug shows that bookings for the vaccine have risen significantly over the past year.

Interestingly, some of this demand is coming from people who are not just worried about the shingles rash. Many patients are choosing to pay for the vaccine—which can cost around £450 for those not eligible for a free NHS dose—because of recent studies suggesting a possible link between the vaccine and a lower risk of dementia. While these studies do not prove that the vaccine prevents dementia, some researchers have reported a potential reduction in risk of up to 20%.

Experts remain cautious about these findings. The shingles vaccine is not currently approved for the prevention of dementia, and it is important for the public to understand the difference between scientific interest and medical proof. John Todd, a professor of precision medicine at the University of Oxford, noted that while the idea of a vaccine helping with dementia is exciting, it is still a developing area of research. For many patients, however, the possibility of even a small amount of protection is enough to encourage them to get the shot.

As the winter months approach, health officials are focusing on two main messages. First, those who are eligible for a free flu vaccine should get it as soon as possible to ensure they are protected before the virus reaches its peak. Second, while the interest in new health benefits from existing vaccines shows how much people care about their long-term well-being, it is vital to rely on advice from medical professionals.

Looking ahead, researchers will continue to study both the flu virus and the long-term effects of the shingles vaccine. Last year, the flu vaccination program in England successfully prevented about 100,000 hospital admissions and 7,000 deaths. Experts hope that by encouraging people to take action early, they can achieve similar results this year. Whether it is through the annual flu shot or other preventive measures, the goal remains the same: to keep the population as healthy as possible during the colder months.